Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001415889-25-001009
Filing Date
2025-01-07
Accepted
2025-01-07 16:53:02
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 16489
2 JOINT FILING AGREEMENT ex-99-01072025_090100.htm EX-99.1 3260
  Complete submission text file 0001415889-25-001009.txt   21484
Mailing Address 100 CAMBRIDGEPARK DRIVE SUITE 101 CAMBRIDGE MA 02140
Business Address 100 CAMBRIDGEPARK DRIVE SUITE 101 CAMBRIDGE MA 02140 617-655-6580
Vor Biopharma Inc. (Subject) CIK: 0001817229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-92269 | Film No.: 25515503
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 101 MISSION STREET, SUITE 1000 SAN FRANCISCO CA 94105
Business Address 101 MISSION STREET, SUITE 1000 SAN FRANCISCO CA 94105 415-541-0200
Reprogrammed Interchange LLC (Filed by) CIK: 0002050755 (see all company filings)

EIN.: 364889533 | State of Incorp.: CA | Fiscal Year End: 1231
Type: SCHEDULE 13D